Molnupiravir is a ribonucleoside analogue and antiviral agent that is used in the therapy the severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection, the cause of the novel coronavirus disease, 2019 (COVID-19). Molnupiravir therapy is given orally for 5 days early in the course of SARS-CoV-2 infection and has not been linked to serum aminotransferase elevations or to clinically apparent liver injury. It is grouped under the following drug class(es): Nucleosides. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Lagevrio and molnupiravirum. Its PubChem CID is 145996610.
Molnupiravir
| CAS No | 2492423-29-5 |
|---|---|
| Molecular Formula | C13H19N3O7 |
| Molecular Weight | 329.31 g/mol |
| Synonyms | [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Molnupiravir is a ribonucleoside analogue and antiviral agent that is used in the therapy the severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection, the cause of the novel coronavirus disease, 2019 (COVID-19).
The listed CAS number is 2492423-29-5.
The listed molecular formula is C13H19N3O7.
The listed molecular weight is 329.31 g/mol.
[(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate.
The source lists Lagevrio and molnupiravirum.